A carregar...
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
Use of the inhibitor of ALK fusion onco-protein, crizotinib (PF02341066), has achieved impressive clinical efficacy in patients with ALK-positive non-small cell lung cancer. Nevertheless, acquired resistance to this drug occurs inevitably in approximately a year, limiting the therapeutic benefits of...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4026079/ https://ncbi.nlm.nih.gov/pubmed/24556908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.28162 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|